Browsing by Author "Canhoroz, Mustafa"

Now showing 1 - 19 of 19

A case of conjunctival melanoma presenting with breast metastasis
(Derman Medical Publ, 2015-09-01) Canhoroz, Mustafa; Yoğurt, İsmail; Gökgöz, Şahsuvar; Kanat, Özkan; Topal, Uğur; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.
Most breast masses arise from the breast. Metastasis to the breast is fairly uncommon, but can occur in breast skin and parenchyma. In particular, leukemia and lung cancers, and MM may metastasize to the breast. Breast metastasis might be the first symptom or may occur during the course of other malignancies. Our case presented with a fixed mass in the upper-medial quadrant of her left breast during regular follow-up visits. The mean time to breast metastasis in patients with MM is 62 months (13-178). In our case this time was 48 months. In a case series with 7 patients hematological malignancies (Hodgkin lymphoma, non-Hodgkin lymphoma, and leukemia) were the leading cause of breast metastasis, whereas in only 1 case the cause was MM. In another case series of 15 MM patients with metastasis to the breast, the primary tumor was frequently localized to the upper extremities and trunk. In a report of 250 conjunctival MM cases the mortality rate was significantly higher in patients with tumors >4 mm in vertical thickness. In another 45-case MM series tumors with a diameter >10 mm were associated with higher mortality rates. In our case the thickness of the tumor was 5 mm. In conclusion, histopathological evaluation should be mandatory in patients with known primary malignancies in order to differentiate new primary tumors, metastases, and benign tumors.
Cisplatin plus etoposide in the adjuvant treatment of patients with non small cell lung cancer
(Derman Medical Publ, 2014-09-01) Çubukcu, Erdem; Canhoroz, Mustafa; Ölmez, Ömer Fatih; Kanat, Özkan; Kurt, Ender; Erol, Muharrem; Çubukcu, Sinem; Yorulmaz, Nadide; Bayram, Sami; Evrensel, Türkkan; Manavoğlu, Osman; ÇUBUKÇU, ERDEM; Canhoroz, Mustafa; Ölmez, Ömer Fatih; Kanat, Özkan; Kurt, Ender; Erol, Muharrem; ÇUBUKÇU, SİNEM; Yorulmaz, Nadide; BAYRAM, AHMET SAMİ; EVRENSEL, TÜRKKAN; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-9732-5340; JGT-4101-2023; CJW-6018-2022; DJG-4827-2022; CYM-0930-2022; DAS-3088-2022; JEN-3243-2023; JJB-0254-2023; GKI-1183-2022; EMY-5874-2022; AAJ-1027-2021; FLP-9613-2022
Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE) combination in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated. The disease-free survival was 10 (1-114) months and the median overall survival was 18 (3-114) months. Discussion: Based on our limited experience, we concluded that PE regimen is safe and effective as adjuvant therapy for patients with NSCLC.
Clinical significance of adiponectin expression in colon cancer patients
(Wolters Kluwer Medknow Publications, 2014-06) Canhoroz, Mustafa; Avcı, Nilüfer; Kanat, Özkan; Ölmez, Ömer Fatih; Manavoğlu, Osman; Çubukçu, Erdem; Erdem; Buluç, Emine; Saraydaoğlu, Özlem; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; AAH-9701-2021; 56315995000; 15074395500
Purpose: Surgery is the definitive treatment for early colon cancers. Adjuvant therapies are used with the aim of eradicating micrometastases and improving cure rates. Recent studies have proposed that adiponectin might be responsible for obesity-related malignancies. We investigated the prognostic value of this cytokine. Materials and Methods: Patients who underwent surgical removal of stage II or III (TNM staging) primary tumors and were followed for at least three years were included in the study given adequate specimen for immunohistochemical evaluation. Based on these criteria, 53 patients were included. Results: Mean age was 58.3 +/- 10.1 years (35-78 years). The mean follow-up time was 41 months (10-96 months). Immunohistochemical evaluation identified 21 patients (39.6%) with cytoplasmic adiponectin present in their specimens. The rates of recurrence were 42.9% (9/21) and 34.4% (11/32) in patients with and without adiponectin expression, respectively. In cases with adiponectin expression, mean disease - free survival was 60.3 +/- 9.03 months, and in cases without adiponectin expression, mean disease -free survival was 68.7 +/- 6.67 months (P = 0.414). Mean overall survival of patients with adiponectin expression was 65 months compared to 67 months for patients without (P = 0.786). Conclusion: Adiponectin, which is secreted by adipose tissue, may have a role in the development and progression of cancer via its pro-apoptotic and/or anti-proliferative effects. Adiponectin expression in tumor tissues is likely to have a negative effect on disease free survival in patients with stage II/III colon cancer; however, no statistically significant effect was demonstrated.
Comparison of second line treatment outcomes between sensitive and refractory small cell lung cancer patients: A retrospective analysis
(Elsevier, 2012-09) Korkmaz, Taner; Seber, Selçuk; Sarı, Eyüp; Ustaalioğlu, Başak Oven; Kefeli, Umut; Balvan, Özlem; Gümuş, Mahmut; Yaşar, Nurgül; Turhal, Nazım Serdar; Canhoroz, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: A retrospective analysis
(Springer, 2013-07) Korkmaz, Taner; Seber, Selçuk; Kefeli, Umut; Sarı, Enes; Öven, Bala Başak; Yıldırım, Emre; Yaşar, Nurgül; Balvan, Özlem; Şener, Nur Dinç ; Yüksel, Sinemis; Güven, Aslıhan Mert; Polat, Özge; Yumuk, Perran Fulden; Gümüş, Mahmut; Turhal, Nazım Serdar; Canhoroz, Mustafa; Aydın, Dinçer; Kanat, Özkan; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; CJW-6018-2022; CCE-1550-2022; CYM-0930-2022; 52663246200; 55438191100; 55881548500
Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods: We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results: Median age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion: Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
Comparison of three different treatment modalities in the management of cancer cachexia
(Sage Publications, 2013) Kanat, Özkan; Çubukçu, Erdem; Avcı, Nilüfer; Budak, Ferah Ah; Ercan, İlker; Canhoroz, Mustafa; Ölmez, Fatih; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı.; 55881548500; 53986153800; 55390409800; 6701913697; 6603789069; 52663246200; 57225252501
Aims and background. The optimal treatment of cancer cachexia remains unknown. In this study, we compared the efficacy of three different treatment modalities in the management of cancer cachexia. Methods. Sixty-two assessable cachectic cancer patients were randomized to one of the following three arms: 1) megesterol acetate (MA) plus meloxicam (n = 23); 2) MA plus meloxicam plus oral eicosapentaenoic acid (EPA)-enriched nutritional supplement (n = 21); or 3) meloxicam plus oral EPA-enriched nutritional supplement (n = 18). Treatment duration was 3 months. Results. The treatment arms were well balanced at baseline. The primary efficacy (body weight and lean body mass) and secondary efficacy (body mass index, quality of life, and serum levels of IL-6 and TNF-alpha) parameters improved after treatment in all three arms. There were no statistically significant differences between treatment groups in the mean percentage changes in all efficacy parameters from baseline to end of study. Conclusions. MA plus meloxicam or EPA supplement plus meloxicam may be effective treatment options in the management of cancer cachexia. The combined use of these agents does not provide further advantages.
Correlation of high FDG uptake in PET/CT with poor prognosis in metastatic gastric adenocarcinoma.
(Lippincott Williams & Wilkins, 2011-05-20) Korkmaz, Taner; Seber, S.; Bilici, Ahmet; Okutur, Kerem; Toptaş, Tayfun; Başaran, Gül Atalay; Dede, Fuat; Yumuk, Perran Fulden; Dane, Faysal; Kanitez, Metin; Kanat, Oe; Gümüş, Mahmut; Demir, Gökhan; Turhal, Nazım Serdar; Canhoroz, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.
Efficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors
(Derman Medical Publ, 2014-07-01) Çubukcu, Sinem; Kanat, Özkan; Çubukcu, Erdem; Ölmez, Ömer Fatih; Canhoroz, Mustafa; Avcı, Nilüfer; Hartavi, Mustafa; Deligönül, Adem; Seyhan, Serdar; Ayyıldız, Aylin; Taşdemir, Ünal; Manavoğlu, Osman; ÇUBUKÇU, SİNEM; Kanat, Özkan; ÇUBUKÇU, ERDEM; Ölmez, Ömer Fatih; Canhoroz, Mustafa; Avcı, Nilüfer; Hartavi, Mustafa; DELİGÖNÜL, ADEM; Seyhan, Serdar; Ayyıldız, Aylin; Taşdemir, Ünal; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakultesi/İç Hastalıkları Anabilim Dalı,; Uludağ Üniversitesi/Tıp Fakultesi//Tıbbi Onkoloji Bilim Dalı.; JJB-0254-2023; JRU-4028-2023; JGT-4101-2023; DJG-4827-2022; CJW-6018-2022; CCT-7946-2022; CUI-5353-2022; JHC-1731-2023; DSI-5869-2022; KGG-2754-2024; KBV-2934-2024; FLP-9613-2022
Aim: In this study, the efficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors (GISTs) was investigated. Material and Method: A total of 11 imatinib-resistant GIST patients who have sufficient information about their medical treatment and outcome were retrospectively analyzed. Results: Partial response was observed in only two patients, and five patients achieved stable disease. Progression free survival and overall time was 8.8 months and 12 months, respectively. Sunitinib was relatively well tolerated. Almost all patients experienced one or more treatment-related adverse event. Discussion: Based on our limited experience, we concluded that sunitinib is reasonable treatment option for patients with imatinibresistant GIST.
Identification of prognostic factors in patients with metastatic gastrointestinal stromal tumors
(Imprimatur Publications, 2012) Çubukçu, Erdem; Ölmez, Ömer Fatih; Avcı, Nilüfer; Canhoroz, Mustafa; Kurt, Ender; Kanat, Özkan; Evrensel, Türkkan; Manavoǧlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; 53986153800; 26435400000; 55390409800; 52663246200; 7006207332; 55881548500; 6603942124; 6602587152
Purpose: Gastrointestinal stromal tumors (GISTs) have a complex biology which is reflected by a marked clinical heterogeneity. Thus, there has been great interest in identifying prognostic factors influencing tumor recurrence and survival. The aim of this study was to identify potential clinical and immunohistochemical prognostic factors that may affect survival and treatment outcomes inpatients with metastatic GISTs. Methods: Between 2000 and September 2011, a total of 41 patients with metastatic GISTs (29 males and 12 females; mean age: 57.4 +/- 11.8 years; range 29-74) were referred to the Department of Oncology, Uludag University Medical School. Survival analysis for a number of potential prognostic factors was made with the main outcome results of progression-free survival (PFS) and overall survival (OS). Results: The most common sites of isolated metastases comprised the liver (n=18), followed by lymph nodes (n=5), the omentum (n=1), and the mesothelium (n=1). The remaining patients had metastases at multiple sites. Cox regression analysis identified ileal location as the only significant predictor of poor PFS both after first-line (p=0.023) and second-line therapy (p=0.016). Tumor location in the ileum (p=0.025) and S100 immunoreactivity (p=0.041) were both independent predictors of OS. Conclusion: Tumor site and S100 positivity were the main significant independent predictors of clinical outcomes in patients with metastatic GISTs treated by standard of care.
Lokal ileri mesane kanserinde adjuvan kemoterapi: 32 olgunun retrospektif analizi
(Uludağ Üniversitesi, 2011-08-03) Çubuk, Erdem; Canhoroz, Mustafa; Ölmez, Ömer Fatih; Avcı, Nilüfer; Çubukçu, Sinem; Akçalı, Ünsal; Sakallı, Mustafa; Bayrak, Muharrem; Kanat, Özkan; Kurt, Ender; Evrensel, Türkkan; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Bilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
Bu çalışmada, lokal ileri mesane kanseri nedeniyle adjuvant kemoterapi alan hastalar retrospektif olarak analiz edildi. Toplam 32 hasta gemsitabin (%18.8), sisplatin+gemsitabin (%50), carboplatin+gemsitabin (%15.6) veya MVAC (Metotreksat, vinblastin, doksorubisin ve sisplatin) (%15.6) tedavisi aldı. Tedaviler sırasında en sık görülen yan etki kemik iliği toksisitesi idi. Tedaviye bağlı ölüm gözlenmedi. Medyan genel ve hastalıksız sağkalım süreleri sırasıyla 23 ay (18.7-27.4) ve 17.8 ay (12.7-22.9) idi. Verilerimizin literatür ile uyumlu olduğu sonucuna varıldı.
Octogenarians: Looking closer to a new group of cancer patients
(Güneş Kitabevi, 2013) Canhoroz, Mustafa; Kanat, Özkan; Evrensel, Türkkan; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; 55881548500; 6603942124
Opere olmuş kolon kanseri hastalarında tümörlü dokuda adiponektin ekspresyonunun prognostik değeri
(Uludağ Üniversitesi, 2011) Canhoroz, Mustafa; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Tıbbi Onkoloji Bilim Dalı.
Adiponektinin obezite ile ilişkili malignitelerin oluşumu ve progresyonunda anahtar rol oynayabileceğini düşündüren yayınlar vardır. Etiyolojik bir faktör olarak değerlendirilen adiponektinin opere kolon tümörlü hastalarda prognostik değeri araştırıldı.Merkezimizde 1997-2007 yılları arasında kolon kanseri nedeni ile opere edilmiş evre II ve III 53 hastanın parafin bloklarında İmmünohistokimyasal olarak adiponektin ekspresyonu ve prognoz üzerine olan etkileri değerlendirildi.Olguların 32'si (%60.4) erkek, 21'i (%39.6) kadın olup ortalama yaşı 58.3±10.1 (35- 78). Olguların ortalama takip süresi 41 ay (10 - 96 ay) idi. TNM sınıflamasına göre olguların 28'inin (%52.8) evre II ve 25'inin (%47.2) evre III olduğu belirlendi. İmmünohistokimyasal inceleme sonucunda 21 (%39.6) vakada tümör dokusunda adiponektin ile boyanma izlendi. Boyanmalar sitoplazmik olarak görüldü. Adiponektin ekspresyonunun olduğu 21 vakadan 9'unda (%42.9) nüks gelişirken, ekspresyonu olmayan 32 vakadan 11'inde (%34.4) nüks gözlendi. Ortalama HSK adiponektin ekspresyonu varlığında 60.3±9.03 ay iken yokluğunda 68.7±6.67 ay olarak hesaplandı (p:0.414).Epidemiyolojik çalışmalarda düşük adiponektin seviyelerinin meme, endometriyum, prostat ve kolorektal kanserlerde artmış risk ile ilişkisi gösterilmiştir. Adiponektin etkilerini hem kanser hücrelerini direkt etkileyerek hem de tüm vücutta insülin duyarlığını etkileyerek dolaylı olarak gösterir. Tümör dokusunda adiponektin ekspresyonun HSK üzerinde olumsuz etkisi gösterilse de ek çalışmalar ile desteklenmesi gerekmektedir.
Paclitaxel carboplatin in elderly patients with advanced non-small cell lung cancer
(Derman Medical Publ, 2012-07-01) Kanat, Özkan; Çubukcu, Erdem; ÇUBUKÇU, ERDEM; Aksoy, Savas; Çubukcu, Sinem; ÇUBUKÇU, SİNEM; Canhoroz, Mustafa; Karadağ, Oya; Alkış, Nihan; Manavoğlu, Osman; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.
Aim: In this study, the safety and tolerability of paclitaxel and carboplatin (PC) regimen in elderly patients with advanced non -small cell lung cancer (NSCLC) was investigated. Material and Method: Elderly patients (ages a70 years) who received PC for stage III (n=111 or IV (n=34) NSCLC were evaluated retrospectively. Results: There were 43 males and 2 females, with a median age of 75.5 (range, 70-62). The response rate was 40%. The median overall survival time and progression-free survival time was 13 months and 8.5 months, respectively. One-year survival rate was 51%. Treatment was well tolerated by the patients. The most frequent side effect observed was grade 3 or 4 neutropenia (57.795). There was no treatment related death. Discussion: PC regimen may be a good alternative for the treatment of elderly patients with advanced NSCLC.
Primary small cell carcinoma of the breast: Report of seven cases and review of the literature
(Sage Publications, 2011-07) Kılıçkap, Saadetin; Korkmaz, Taner; Öven, Bala Başak Ustaalıoğlu; Kanat, Özkan; Canhoroz, Mustafa; Çubukçu, Erdem; Tolunay, Şahsine; Evrensel, Türkkan; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-9732-5340; AAI-1612-2021; AAJ-1027-2021; 55881548500; 52663246200; 53986153800; 6602604390; 6603942124; 6602587152
Aims and background. The aim of the study was to analyze the clinicopathological characteristics, treatment modalities, and clinical outcome of patients with primary small cell carcinoma of the breast. Methods. Fifty-three cases of primary small cell carcinoma of the breast were identified; 7 cases in this series and 46 from the English-language medical literature. Results. There were 52 females and 1 male. The mean age was 53 years. Tumor size ranged from 1 to 18 cm (mean, 4.53). Axillary node metastasis was present in 61.7%. Only one patient had distant metastases at presentation. The presence of hormone receptors was reported in 24.5% of the tumors. Modified radical mastectomy was the most common surgical procedure and was performed in 50.9% of the patients. Adjuvant radiotherapy was administered to 39.6% of the patients, and 69.8% underwent chemotherapy. Thirteen percent of patients received adjuvant tamoxifen therapy. The mean follow-up was 20.75 months (range, 3-60), and 10 of 53 cases (18.9%) died of metastatic disease. Conclusions. The prognosis of primary small cell carcinoma of the breast largely depends on the initial stage of the disease. Multimodality treatment including surgery, radiotherapy and chemotherapy seems to be the most appropriate strategy for early disease. Chemotherapy is usually unsuccessful in treating metastatic disease.
Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer
(Imprimatur Publications, 2013-01-29) Ölmez, Fatma; Çubukçu, Erdem; Kanat, Özkan; Ölmez, Ömer Fatih; Kabul, Selva; Canhoroz, Mustafa; Avcı, Nilüfer; Deligönül, Adem; Hartavi, Mustafa; Çubukçu, Sinem; Kurt, Ender; Evrensel, Türkkan; Gökgöz, Şehsuvar; Manavoǧlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; DJG-4827-2022; ETP-1691-2022; CYM-0930-2022; CAH-9737-2022; CJW-6018-2022; CCT-7946-2022; ESM-4544-2022; CUI-5353-2022; CMF-4464-2022; DAS-3088-2022; EXK-4525-2022; FLP-9613-2022; 53986153800; 55881548500; 55779185600; 56113027300; 52663246200; 55390409800; 37088030300; 55370753300; 55778484600; 7006207332; 6603942124; 6603238737; 6602587152
Purpose: To determine the prognostic significance of estrogen receptor (ER), progesterone receptor (PR), HER2/neu, Ki-67, and nm23 immunohistochemical expression with respect to progression free survival (PFS) and overall survival (OS) in Turkish patients with invasive breast cancer (IBC). Methods: Patients with IBC (n = 81; mean age = 51.9 ± 11.1 years) were prospectively enrolled at the Department of Oncology, Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections. Results: We did not find any significant association between immunohistochemical expression of ER, PR, HER2/neu, Ki-67, and nm23 and the baseline characteristics of IBC patients. The median patient PFS was 30 months (range 22-45), and the median OS was 32 months (range 23-46). Stratification of the patient population according to nm23 immunohistochemical expression revealed a statistically significant difference in terms of both OS (p < 0.05) and DFS (p < 0.05). Multivariate Cox regression analysis indicated that tumor grade, axillary lymph node status, and nm23 immunohistochemical expression were the 3 main independent prognostic factors for PFS and OS in IBC patients. Conclusion: Reduced nm23 immunohistochemical expression is an independent negative prognostic factor for OS and PFS. Patients with negative nm23 expression may require a more intensive follow-up.
Prognostic significance of human epidermal receptor (HER)-3 immunohistochemical expression in patients with metastatic breast cancer
(Asian Pacific Organization for Cancer Prevention, 2013) Ölmez, Fatma; Ölmez, Ömer Fatih; Evrensel, Türkkan; Çubukçu, Erdem; Uğraş, Nesrin; Avcı, Nilufer; Canhoroz, Mustafa; Deligönül, Adem; Hartavi, Mustafa; Çubukçu, Sinem; Tolunay, Şahsine; Kurt, Ender; Kanat, Özkan; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; AAH-2716-2021; AAI-1612-2021; DJG-4827-2022; ETP-1691-2022; CCT-7946-2022; CJW-6018-2022; ESM-4544-2022; CUI-5353-2022; CMF-4464-2022; DAS-3088-2022; CYM-0930-2022; FLP-9613-2022; 26435400000; 6603942124; 53986153800; 55386535600; 55390409800; 52663246200; 37088030300; 55370753300; 55778484600; 6602604390; 7006207332; 55881548500; 6602587152
Background: Previous reports have shown that human epidermal receptor (HER)-3 overexpression may be associated with poor prognosis in patients with breast cancer, but results have been conflicting. In this study, we sought to investigate the prognostic significance of HER-3 immunohistochemical expression in patients with metastatic breast cancer. Methods: We retrospectively analyzed HER-3 immunohistochemical expression profiles in 45 paraffin-embedded specimens from patients who had been treated between 1996 and 2006 in the Department of Oncology of the Uludag University School of Medicine, Bursa, Turkey. Membranous or cytoplasmic dominant expression patterns of HER-3 were analyzed using the Rajkumar score and a cytoplasmic 4-point scoring system, respectively. Progression-free survival (PFS) and overall survival (OS) served as the main outcome measures. Results: The median PFS in the study participants was 9 months (interquartile range: 4.5-13 months), whereas the median OS was 20 months (interquartile range: 7.5-28 months). Categorization of the patient population according to HER-3 positive immunohistochemical expression did not reveal any statistically significant difference in terms of both PFS (p=0.70) and OS (p=0.81). The results of multivariable Cox regression analysis indicated that tumor size was the only independent predictor of PFS, whereas estrogen and progesterone receptor status was independently associated with OS. Conclusions: HER-3 immunohistochemical expression did not correlate with outcomes in Turkish patients with metastatic breast cancer. Although our results suggest that HER-3 expression in cancer specimens is not of prognostic significance, further prospective studies are warranted to confirm these results.
The association between serum adiponectin level and glycemic control
(Derman Medical Publ, 2012-04-01) Güzelbulut, Fatih; Dalbeler, Aysegül Gök; Babacan, Gül; Canhoroz, Arzu; Canhoroz, Mustafa; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; 0000-0003-4889-208X; AAF-9450-2019
Aim: In last decades we recognize that the fat tissue isn't only a depot also an active endocrine tissue. The fat cell isn't a passive cell, it has an unsteady volume that changes according to daily energy uptake, and releases cytokines and hormones to extracelluler fluid. Patients with type 2 diabetes have distinctly increased atherosclerotic risk. This risk is associated with hyperglycemia, dyslipidemia and increased inflamation. Adiponectine that only secretes from adipose tissue, has a suspected role in this process. In this trial we looked for if there is any effect of adiponectin on glycemic control. Material and Method: The patients had been divided in three groups; diabetics with good glycemic control (n: 20), diabetics with bad glycemic control (n: 34) and non diabetics (n: 19). All patients age, sex, history of diabetes, BMI, waist circumference, fat mass, fat % had recorded then serums had taken for adiponectin and HbA1c assesment. Results: There was no correlation with adiponectine and HbA1c. Serum adiponectine levels were similar in three groups (659,29 +/- 98,57; 694,09 +/- 144,85; 609,5 +/- 168,24; p: 0,117). Discussion: The results showed that there is no significant effect of adiponectin on glycemic control contrary to expectations. The low levels of serum adiponectin isn't cause of the metabolic syndrome and insulin resistance, it's the result of the process that results in metabolic syndrome.
The prevalance of herbal product use as a alternative medicine among cancer patients in Turkey
(Derman Medical Publ, 2015-05-01) Avcı, Nilufer; Canhoroz, Mustafa; Kanat, Özkan; Guru, Mine Sibel; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Anabilim Dalı.
Aim: We investigated the prevalance of herbal product use in cancer patients who were followed up and treated at our center. Material and Method: A total of 271 patients were enrolled in this study. Patients asked to complete a questionnaire form and the stage of the patients and the treatment given were recorded following the delivery of the questionnaire form by the investigator. Results: Herbal products were used by 97 (35.7%) of 271 patients who completed the questionaire. The most common herbal products used alone or in combination were urtica urens, ginger, bee pollen, green tea. The highest use rate was observed in patients between the age of 40 and 49 (54%, p= 0.099). The rate also was found to increase in in paralel to the increased level of income i. e 32% in patients with a lower income level, 35% patients with a moderate income level, and 44% in patients with a high income level (p= 0.386). As the education level increased, the rate of use of herbal products also increased (p= 0.023). Discussion: The use of herbal products is rather prevalent among cancer patients. There is a need to increase the awareness of the physicians regarding herbal products and educate the population as a whole.
XRCC1 gene polymorphisms and risk of lung cancer in Turkish patients
(Kamla-Raj Enterprises, 2012-06) Karkucak, Mutlu; Yakut, Tahsin; Evrensel, Türkkan; Deligönül, Adem; Gülten, Tuna; Ocakoğlu, Gökhan; Kurt, Ender; Kanat, Özkan; Çubukcu, Erdem; Şehitoğlu, İbrahim; Canhoroz, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Genetik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; AAH-5180-2021; ABF-8955-2021; 35388323500; 6602802424; 6603942124; 37088030300; 6505944216; 15832295800; 7006207332; 55881548500; 53986153800; 36553239400; 52663246200
Polymorphisms in the X-ray repair cross complementing 1 (XRCC1) gene have been found to be associated with susceptibility to various types of cancers. We investigated the association between the XRCC1 gene Arg399Gln polymorphism and the susceptibility to lung cancer in Turkish patients. To determine the association of this polymorphism with the risk of lung cancer in Turkish patients, a hospital-based case-control study was designed, involving 67 patients with lung cancer and 60 control subjects with no cancer history who were matched for age and gender. XRCC1 genotypes (Arg/Arg, Arg/Gln, and Gln/Gln) were determined using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) analysis on genomic DNA. No statistically significant relationship was determined between the lung cancer and control groups (p>0.05). Among the patients, 61% were Arg/Arg, 28% were Arg/Gln, and 11% were Gln/Gln. Among the controls, 50% were Arg/Arg, 38% were Arg/Gln, and 12% were Gln/Gln. There was no difference in the distribution of XRCC1 genotypes or the frequencies of the Arg (75% versus 69%) and Gln (25% versus 31%) alleles between the lung cancer patients and controls. Our results suggest that the XRCC1 gene Arg399Gln polymorphism is not associated with an increased risk for the development of lung cancer in Turkish patients.